News

September is 'blood cancer awareness month', and we had the opportunity to take part in a number of conferences, workshops and summits to raise awareness of who we are and to promote our work in [...]

“If the study can confirm the benefit of a PET response adapted approach, it will establish a new standard of care for follicular lymphoma globally”, said A/Prof Trotman.

On Wednesday 25 July, Federal Health Minister Greg Hunt announced $3.2 million in funding to four clinical trials that will give adolescent and young adult cancer patients access to cutting-edge [...]

On Monday 11 June, the Chairman of the ALLG, Mr Peter T Kempen was announced as an honorary Member (AM) in the general division of the Order of Australia honours for significant service to the [...]

The Australasian Leukaemia and Lymphoma Group (ALLG) held its May 2018 Scientific Meeting (SM) in Melbourne with 270 members in attendance.

Late last year the ALLG welcomed the release of the Select Committee report into Funding for Research into Cancers with Low Survival Rates, calling on the Federal Government to make research into [...]

Professor Michael Pfreundschuh, one of the leading experts in the world of Lymphoma research and treatment, sadly passed away on March 5th 2018.

This year, almost 16,000 Australians will begin a long and gruelling journey with blood cancer. Decades of research have led to vastly improved outcomes for blood cancer patients with survival [...]

The Australasian Leukaemia & Lymphoma Group (ALLG) welcomed the November 2017 release of the Select Committee Report into funding for research into cancers with low survival rates.

Professor Mark Hertzberg recently retired as Chair of The Australasian Leukaemia & Lymphoma Group (ALLG) Scientific Advisory Committee (SAC). Prof Hertzberg, who took the role as Chair in 2010 [...]

During November 2017, The Australasian Leukaemia & Lymphoma Group (ALLG) held its biannual Scientific Meeting (SM) in Sydney.

The Australasian Leukaemia & Lymphoma Group (ALLG) applauded the launch of the landmark report called “Economic evaluation of investigator-initiated clinical trials conducted by networks”.